Middle East respiratory syndrome coronavirus spike protein delivered by modified vaccinia virus Ankara efficiently induces virus-neutralizing antibodies
Fei Song, Robert Fux, Lisette B Provacia, Asisa Volz, Markus Eickmann, Stephan Becker, Albert D M E Osterhaus, Bart L Haagmans, Gerd Sutter, Fei Song, Robert Fux, Lisette B Provacia, Asisa Volz, Markus Eickmann, Stephan Becker, Albert D M E Osterhaus, Bart L Haagmans, Gerd Sutter
Abstract
Middle East respiratory syndrome coronavirus (MERS-CoV) has recently emerged as a causative agent of severe respiratory disease in humans. Here, we constructed recombinant modified vaccinia virus Ankara (MVA) expressing full-length MERS-CoV spike (S) protein (MVA-MERS-S). The genetic stability and growth characteristics of MVA-MERS-S make it a suitable candidate vaccine for clinical testing. Vaccinated mice produced high levels of serum antibodies neutralizing MERS-CoV. Thus, MVA-MERS-S may serve for further development of an emergency vaccine against MERS-CoV.
Figures
Source: PubMed